Tirzepatide (Mounjaro) 10mg Vial Premixed

WE ONLY SHIP TO THE UK (EXC NI)

We will also include some syringes.

THIS LISTING IS FOR 1 PREMIXED VIAL OF 10mg TIRZEPATIDE (MOUNJARO) WITH 1ml BACTERIOSTATIC WATER.

If you're new to this medicine this vial will last you 4 weeks, depending on your dosage increase.

Each 0.25ml on the syringe will give a 2.5mg dose. Most people start on 2.5mg per week and some people can stay on this dose but some people may find they need to up to 5mg a week after a while as their body adjusts. You can go up to 15mg a week maximum but most people find 5mg at most to be enough.

Tirzepatide, a novel medication developed by Eli Lilly and Company, is making headlines for its remarkable efficacy in promoting weight loss. Originally intended for type 2 diabetes management, this dual incretin receptor agonist has demonstrated exceptional potential in treating obesity, offering hope to millions struggling with weight management.

Dosage and Administration

Tirzepatide is administered via subcutaneous injection once weekly. The dosage is gradually increased to mitigate gastrointestinal side effects and improve tolerance. The typical dosage regimen is as follows:

1. Starting Dose: 2.5 mg once weekly for the first 4 weeks.
2. Initial Increase: 5 mg once weekly for the next 4 weeks.
3. Subsequent Increases: Depending on the patients response and tolerance, the dose can be increased in increments of 2.5 mg every 4 weeks. The maximum recommended dose is 15 mg once weekly.

Patients are advised to follow the dosage escalation plan closely under the supervision of their healthcare provider to optimize efficacy and minimize side effects.

Mechanism of Action

Tirzepatide is unique due to its dual action on two key incretin hormones: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). These hormones naturally regulate insulin secretion and appetite. By activating both GIP and GLP-1 receptors, tirzepatide enhances insulin secretion, decreases glucagon levels, slows gastric emptying, and reduces appetite. This comprehensive approach not only aids in blood glucose control but also significantly impacts weight management.

Clinical Trials and Efficacy

The efficacy of tirzepatide for weight loss has been extensively studied in clinical trials, particularly in the SURMOUNT program. The SURMOUNT-1 trial, focusing on adults with obesity or overweight without diabetes, yielded impressive results. Participants treated with tirzepatide experienced substantial weight reductions that surpass those seen with current weight loss medications.

In this trial, individuals receiving tirzepatide lost an average of 15-22.5% of their body weight over 72 weeks, depending on the dosage. These outcomes are particularly notable when compared to traditional weight loss drugs, which typically result in weight loss of 5-10%. The significant reduction in body weight highlights tirzepatide's potential as a powerful tool in combating obesity.


Impact on Obesity

The profound weight loss effects of tirzepatide can have wide-ranging benefits for individuals struggling with obesity. Obesity is a complex and chronic condition that increases the risk of numerous health issues, including type 2 diabetes, cardiovascular diseases, and certain cancers. Effective weight management can lead to improved overall health, reduced comorbidities, and enhanced quality of life.

Tirzepatide is poised to revolutionize the field of obesity treatment with its dual-action mechanism and remarkable efficacy in promoting weight loss. By targeting both GIP and GLP-1 receptors, it offers a multifaceted approach to weight management, addressing both metabolic and behavioral aspects of obesity. As research progresses and regulatory approvals are sought, tirzepatide could become a cornerstone in the fight against obesity, offering hope and improved health outcomes for millions of individuals struggling with excess weight.